These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10936517)

  • 21. Development of a new pharmacophore model that discriminates active compstatin analogs.
    Chiu TL; Mulakala C; Lambris JD; Kaznessis YN
    Chem Biol Drug Des; 2008 Oct; 72(4):249-56. PubMed ID: 18844671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency.
    Qu H; Magotti P; Ricklin D; Wu EL; Kourtzelis I; Wu YQ; Kaznessis YN; Lambris JD
    Mol Immunol; 2011 Jan; 48(4):481-9. PubMed ID: 21067811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity.
    Mannes M; Dopler A; Zolk O; Lang SJ; Halbgebauer R; Höchsmann B; Skerra A; Braun CK; Huber-Lang M; Schrezenmeier H; Schmidt CQ
    Blood; 2021 Jan; 137(4):443-455. PubMed ID: 33507296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural aspects and design of low-molecular-mass complement inhibitors.
    Morikis D; Lambris JD
    Biochem Soc Trans; 2002 Nov; 30(Pt 6):1026-36. PubMed ID: 12440966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-complement activity of oleanolic acid: an inhibitor of C3-convertase of the classical complement pathway.
    Kapil A; Sharma S
    J Pharm Pharmacol; 1994 Nov; 46(11):922-3. PubMed ID: 7897600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of a modified mouse protein with ligand binding properties of its human analog by molecular dynamics simulations: the case of C3 inhibition by compstatin.
    Tamamis P; Pierou P; Mytidou C; Floudas CA; Morikis D; Archontis G
    Proteins; 2011 Nov; 79(11):3166-79. PubMed ID: 21989937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy.
    Zhang Y; Shao D; Ricklin D; Hilkin BM; Nester CM; Lambris JD; Smith RJ
    Immunobiology; 2015 Aug; 220(8):993-8. PubMed ID: 25982307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA).
    Feuillard J; Maillet F; Goldschmidt P; Weiss L; Kazatchkine MD
    Agents Actions; 1991 Mar; 32(3-4):343-6. PubMed ID: 1862751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Solution structure of Compstatin, a potent complement inhibitor.
    Morikis D; Assa-Munt N; Sahu A; Lambris JD
    Protein Sci; 1998 Mar; 7(3):619-27. PubMed ID: 9541394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Species specificity of the complement inhibitor compstatin investigated by all-atom molecular dynamics simulations.
    Tamamis P; Morikis D; Floudas CA; Archontis G
    Proteins; 2010 Sep; 78(12):2655-67. PubMed ID: 20589629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Active sites in complement components C5 and C3 identified by proximity to indels in the C3/4/5 protein family.
    Low PJ; Ai R; Ogata RT
    J Immunol; 1999 Jun; 162(11):6580-8. PubMed ID: 10352274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin.
    Katragadda M; Morikis D; Lambris JD
    J Biol Chem; 2004 Dec; 279(53):54987-95. PubMed ID: 15489226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From discovery to approval: A brief history of the compstatin family of complement C3 inhibitors.
    Mastellos DC; Ricklin D; Sfyroera G; Sahu A
    Clin Immunol; 2022 Feb; 235():108785. PubMed ID: 34147650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement activity in normal rabbit bronchoalveolar fluid. Description of an inhibitor of C3 activation.
    Giclas PC; King TE; Baker SL; Russo J; Henson PM
    Am Rev Respir Dis; 1987 Feb; 135(2):403-11. PubMed ID: 3643768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic peptide inhibitors of complement serine proteases--II. Effects on hemolytic activity and production of C3a and C4a.
    Schasteen CS; McLafferty SA; Glover GI; Han CY; Mayden JC; Liu WS; Levine RP
    Mol Immunol; 1988 Dec; 25(12):1269-75. PubMed ID: 3266292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b.
    Sahu A; Rawal N; Pangburn MK
    Biochem Pharmacol; 1999 Jun; 57(12):1439-46. PubMed ID: 10353266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile.
    Berger N; Alayi TD; Resuello RRG; Tuplano JV; Reis ES; Lambris JD
    J Med Chem; 2018 Jul; 61(14):6153-6162. PubMed ID: 29920096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distal recognition site for classical pathway convertase located in the C345C/netrin module of complement component C5.
    Sandoval A; Ai R; Ostresh JM; Ogata RT
    J Immunol; 2000 Jul; 165(2):1066-73. PubMed ID: 10878385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system.
    Pedersen H; Jensen RK; Hansen AG; Gadeberg TAF; Thiel S; Laursen NS; Andersen GR
    J Biol Chem; 2020 Jun; 295(26):8746-8758. PubMed ID: 32376685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitor of complement, Compstatin, prevents polymer-mediated Mac-1 up-regulation of human neutrophils independent of biomaterial type tested.
    Schmidt S; Haase G; Csomor E; Lütticken R; Peltroche-Llacsahuanga H
    J Biomed Mater Res A; 2003 Sep; 66(3):491-9. PubMed ID: 12918031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.